Key Highlights

• Tenax Therapeutics (NASDAQ: TENX) board approves amendments to employment agreements for certain executives on June 26, 2026.

• Executives may receive severance payments if terminated without cause, including an annual bonus calculated as if 100% of performance goals were achieved.

• New change-in-control plan provides accelerated equity vesting and cash benefits for eligible employees, excluding top executives.

• Revised agreements include enhanced protections during corporate transitions, with benefits tied to specific conditions.

Leadership Terms Revised

Tenax Therapeutics (NASDAQ: TENX) announced updates to its executive compensation framework, modifying employment agreements for select members of its leadership team. The board approved these changes on June 26, 2026, following a review by its compensation committee. The revisions aim to align executive severance and change-in-control provisions with newly established company-wide policies.

Executive Severance Details

Under the revised terms, certain executives may receive severance payments if terminated without cause. The agreements include a pro-rated annual bonus, calculated as if 100% of performance targets were met in the fiscal year of termination. The structure reflects the company’s approach to balancing retention and accountability for its senior leadership.

Change-in-Control Protections

The updated agreements introduce additional safeguards in the event of a change in control. If an executive’s employment ends within a specified period following such an event, they may receive accelerated vesting of equity awards. The terms vary by role, with some executives eligible for extended salary continuation and healthcare reimbursements.

These benefits are contingent upon the execution of a release of claims.

New Employee Plans Adopted

Tenax Therapeutics also implemented a change-in-control plan and a severance plan for eligible employees. The change-in-control plan offers equity acceleration and cash benefits if employment ends within a defined timeframe after a qualifying transaction. The severance plan provides payments for terminations without cause, separate from any change-in-control scenario.

Both plans exclude executive officers, who are covered under their individual agreements.

Board Governance Moves

The board’s decision reflects an effort to standardize compensation practices across the organization. The new plans are designed to support employee retention while aligning with shareholder interests, particularly during periods of corporate transition.

Equity and Bonus Adjustments

The amended agreements for certain executives include provisions for accelerated vesting of outstanding equity awards upon termination. The annual bonus component applies to these executives, maintaining performance-based compensation structures. While the terms share similarities with those available to non-executive employees, they are tailored to reflect leadership responsibilities.

Compliance and Transparency

The updates adhere to Securities Exchange Act requirements, ensuring regulatory compliance. Tenax Therapeutics filed the amendments to provide transparency for investors and regulatory authorities. The changes became effective immediately upon filing, with no additional board approval required.

The move underscores the company’s commitment to governance best practices in the biotech sector.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.